Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Protocol Number:
PAALL0434
Phase:
Phase III
Physician:
Patrick Brown
Purpose:
The overall goal of this study is to see if we can increase the cure rate for T-cell ALL with acceptable side effects of therapy.
Eligibility:
Patients must be between 1-30 years of age Newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and/or IT cytarabine.
Treatment:
Subjects (people participating in the study) will receive a standard treatment plan during Part I of this study. Standard treatment includes chemotherapy. Standard treatment for ALL has several phases. In the first phase, called Induction, we try to remove all visible signs of leukemia and allow normal blood cells to be restored. This is called remission. You have currently completed the Induction phase of therapy. In the middle phases, called Consolidation, Interim Maintenance and Delayed Intensification, we try to deliver a ?knock-out punch? to any remaining leukemia cells. In the final phase, called Maintenance, we try to keep the leukemia from coming back (disease remission is when the leukemia cells seem to have disappeared). All phases of treatment are very important. The total length of treatment is 2 ½ to 3 years, but does vary.
Population:
Both
Last Update
07/30/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer